Cardiovascular Devices

Global Cardiovascular Devices Market to Reach US$80.8 Billion by 2030

The global market for Cardiovascular Devices estimated at US$54.8 Billion in the year 2024, is expected to reach US$80.8 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Surgical Devices, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$58.3 Billion by the end of the analysis period. Growth in the Diagnostic & Monitoring Devices segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.8 Billion While China is Forecast to Grow at 10.6% CAGR

The Cardiovascular Devices market in the U.S. is estimated at US$14.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$17.5 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Cardiovascular Devices Market - Key Trends and Drivers Summarized

Cardiovascular devices are medical instruments and implants used to diagnose, monitor, and treat diseases related to the heart and the vascular system. These devices play a crucial role in managing a wide range of cardiovascular conditions, such as arrhythmias, heart failure, coronary artery disease, and peripheral vascular diseases. The main types of cardiovascular devices include Pacemakers; Implantable Cardioverter Defibrillators (ICDs); Stents; Cardiac Loop Recorders; Ventricular Assist Devices (VADs); Prosthetic Heart Valves; Cardiac Ablation Catheters; Coronary Pressure Monitors; Cardiac Resynchronization Therapy (CRT) Devices, among others. The implantation of cardiac devices has shown substantial benefits in improving the quality of life for patients suffering from cardiac arrhythmias, heart failure, and related conditions. These devices encompass a wide range of technologies tailored to specific patient needs, including pacemakers for managing bradycardia, implantable cardioverter-defibrillators (ICDs) for preventing sudden cardiac death, and left-ventricular assist devices (LVADs) that take over the pumping function of the heart in severe cases. Additionally, developments in cardiac loop recorders, ventricular assist devices, and stents have significantly advanced the field. These devices not only provide critical support for heart function but also play a pivotal role in managing complex cardiac conditions, thereby improving patient outcomes and extending lives.

The systematic review of trials highlighted a substantial improvement in patients` quality of life post-implantation, with the largest gains seen in LVAD and pacemaker recipients. The efficacy of these devices is attributed to their ability to alleviate severe symptoms and improve functional capacity, which is crucial in chronic conditions where quality of life is severely compromised. Furthermore, the studies suggest a growing recognition of quality of life measurements in clinical settings, advocating for their regular assessment to guide therapeutic decisions effectively. This shift is mirrored in the broader medical community, where there is an increasing focus on holistic treatment outcomes that include psychological well-being and patient-centric care, suggesting a paradigm shift towards integrating medical and psycho-social care models.

The growth in the cardiac device market is driven by several factors, including technological advancements that enhance device efficacy and patient safety, and the integration of these devices with digital health technologies for improved patient monitoring and management. The rising prevalence of cardiovascular diseases globally necessitates the development and adoption of advanced therapeutic devices. Additionally, expansions in healthcare infrastructure, particularly in emerging economies, along with evolving regulatory and reimbursement landscapes, are influencing the adoption rates of these technologies. Increased awareness among patients about the benefits of cardiac device therapies and a shift in healthcare provider preferences towards less invasive and more effective treatment options are further catalyzing the market growth. Lastly, substantial investments in research and development by medical device companies are fueling innovations that promise to deliver safer and more efficient cardiovascular devices, thus enhancing overall patient outcomes.

SCOPE OF STUDY:

The report analyzes the Cardiovascular Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Type (Surgical Devices, Diagnostic & Monitoring Devices); Application (Coronary Artery Disease (CAD) Application, Cardiac Arrhythmia Application, Heart Failure Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 74 Featured) -

• Abbott Laboratories
• Abiomed, Inc.
• B. Braun SE
• Baxter International, Inc.
• Biosensors International Group
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Cardinal Health, Inc.
• GE Healthcare
• LivaNova PLC
• Medtronic Plc
• Nano Therapeutics Pvt., Ltd.
• Siemens Healthineers AG
• Teleflex, Inc.
• Terumo Corp
• W. L. Gore & Associates, Inc. (Gore Medical Products Division)

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.